Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pozen’s MT nest

Pozen Inc. is on the way to becoming the poster child for the problems associated with the no research-development only (NRDO) business model, as it has now been turned down twice by the FDA for approval of reformulations or combinations of marketed drugs.

A not approvable letter issued by the FDA last week suggests that the agency does not think the company’s MT 100 - a combination of the approved drugs naproxen and metoclopramide - provides an improvement over naproxen, while it also is concerned with potential side effects associated with metoclopramide.

As with the failure of

Read the full 964 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers